Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BKV Corporation Common Stock (NY:BKV)

22.38 +0.60 (+2.75%)
Official Closing Price Updated: 7:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BKV Corporation Common Stock

BKV Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Earnings Scheduled For May 9, 2025
Via Benzinga
Breaking Down BKV: 7 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
The Analyst Verdict: BKV In The Eyes Of 7 Experts
Via Benzinga
Where BKV Stands With Analysts
Via Benzinga
Forecasting The Future: 12 Analyst Projections For BKV
Via Benzinga
Analyst Expectations For BKV's Future
Via Benzinga
Insiders Bet Big on These Small Cap Stocks
Insiders are buying stocks like CalciMedica and BKV Corporation because they have value and catalysts in 2025 to drive higher share prices. 
Via MarketBeat
Earnings Scheduled For November 12, 2024
Via Benzinga
BKV's Integrated Operations Offer Value, Analyst Highlights Unique 'Closed-Loop' System And Growth Prospects
Truist Securities analyst initiates Buy rating & $24 price target for BKV Corporation, owned by Banpu with potential for future equity sales. 
Via Benzinga
This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Self-Driving Startup Pony.ai Files For U.S. IPO
Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Obesity Drug Developer BioAge Makes Nasdaq Debut
Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.